Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review

Toshiki Terao, Takafumi Tsushima, Daisuke Miura, Daisuke Ikeda, Ami Fukumoto, Ayumi Kuzume, Rikako Tabata, Kentaro Narita, Masami Takeuchi, Kosei Matsue

Research output: Contribution to journalArticlepeer-review

Abstract

Carfilzomib (Cfz) is widely used to treat multiple myeloma. However, real-world data of the incidence of thrombotic microangiopathy (TMA) caused by Cfz is inconsistent (<1–5%). We evaluated 96 consecutive patients who received Cfz to evaluate the incidence of TMA in clinical practice. TMA developed in five patients (5.2%) who were mainly receiving high-dose Cfz (≥56 mg/m2). Based on a literature review, precaution should be taken for Cfz-induced TMA in male patients receiving high-dose Cfz irrespective of the combination therapy, Cfz administration period, and complement level. In conclusion, Cfz-induced TMA might be underestimated in clinical practice, and early intervention should be considered.

Original languageEnglish
Pages (from-to)1102-1110
Number of pages9
JournalLeukemia and Lymphoma
Volume63
Issue number5
DOIs
Publication statusPublished - 2022
Externally publishedYes

Keywords

  • Carfilzomib
  • multiple myeloma
  • thrombotic microangiopathy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review'. Together they form a unique fingerprint.

Cite this